You are here

Artificial Heart Valve Wins FDA Nod

Device reduces complications of valve-replacement procedure

The FDA has approved the SAPIEN 3 transcatheter aortic heart valve for the treatment of high-risk patients with severe, symptomatic aortic stenosis.

The decision was based on positive results from a cohort of the PARTNER II (Placement of AoRTic TraNscathetER Valves II) trial, which enrolled 583 high-risk patients at 29 U.S. sites.

“The PARTNER II study concluded that this new valve reduced several complications associated with the TAVR [transcatheter aortic valve replacement] procedure, such as paravalvular leakage and stroke, and represented a meaningful improvement over data from prior studies with earlier-generation devices,” said co-principal investigator Martin B. Leon, MD, professor of medicine at the Columbia University College of Physicians and Surgeons.

The new valve, available in 20-mm, 23-mm, 26-mm, and 29-mm sizes, has an outer skirt (a cuff of fabric surrounding the valve frame), which provides a seal to address paravalvular leakage, according to its manufacturer, Edwards Lifesciences Corporation. The company expects the product’s launch to be largely completed by the end of the year.

The SAPIEN 3 valve has been commercially available in Europe since January 2014.

Source: Edwards Lifesciences Corp.; June 17, 2015.

Recent Headlines

Statistically Significant Improvement in Excessive Daytime Sleepiness
Researcher Made Himself Guinea Pig to Test the Drug
Treatment Shorter, Less Complicated Than Typical Regimen
Zip Device Faster to Apply, Minimizes Scarring
But a ‘Serendipitous’ Finding Could Provide a Solution
New Drug Could Make Ears “Young” Again
DNA Changes May Help Predict Women at Risk
Finding Could Spur New Targeted Treatments